Speaker Profile
M.D., Ph.D., Executive Director, Chief Scientist , Cancer Immunology, AstraZeneca
Biography
Dr. Dmitry Gabrilovich is a prominent figure in cancer immunology, currently serving as the Chief Scientist in Cancer Immunology at AstraZeneca in Gaithersburg, Maryland. His research primarily focuses on understanding how tumors suppress the immune system and developing innovative immunotherapies to counteract these mechanisms.Dr. Gabrilovich has held several notable academic and research positions as Endowed Professor at the H. Lee Moffitt Cancer Center and The Wistar Institute in Philadelphia, where he also led the Immunology, Microenvironment Metastasis Program.Dr. Gabrilovich's groundbreaking work includes identifying the impaired function of dendritic cells in cancer patients and co-discovering myeloid-derived suppressor cells (MDSCs), which play a significant role in tumor-induced immune suppression. Dr. Gabrilovich was awarded the title of Research Professor by the American Cancer Society in 2019.Dr. Gabrilovich's work continues to influence the field of cancer immunology, particularly in understanding tumor-immune interactions and developing strategies to enhance the efficacy of cancer immunotherapies.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair: Ira Mellman, Medici Therapeutics
PMWC Award Ceremony
• Jedd D. Wolchok, Weill Cornell Medicine
• Suzanne Topalian, Johns Hopkins
• Levi Garraway, Roche
Targeting the Tumor Microenvironment (TME) in Practice: Biomarkers & Combos
• Chair: Ira Mellman, Medici Therapeutics
• Dmitry Gabrilovich, AstraZeneca
Immunotherapy with Personalized Cancer Vaccines: Who, When, How Fast?
• Chair: Suzanne Topalian, Johns Hopkins
• Tal Zaks, Orbimed
• Lelia Delamarre, Genentech
ADCs in the Checkpoint Era: Who Benefits, What to Combine, What to Avoid
• Chair: Shreya Badhrinarayanan, Pfizer
• S. Peter Kang, Daiichi Sankyo
Strategic IP Management in Cell and Gene Therapy: Navigating Legal and Practical Challenges
• Janet Xiao, Morrison & Foerster LLP
Checkpoint 2.0 in Practice: PD-1+VEGF Wins, Resistance Salvage & Biomarker Gates
• Chair: Jedd D. Wolchok, Weill Cornell Medicine
Future Breakthroughs in Immuno-Oncology: New Targets, Modalities & Biomarker Decision Gates
• Chair: Levi Garraway, Roche
